Search Results - "Blanco, Carmina"

Kinase inhibitor-induced cardiotoxicity assessed in vitro with human pluripotent stem cell derived cardiomyocytes by Xian, Hai-Qing, Blanco, Carmina, Bonham, Kristina, Snodgrass, H. Ralph

“…Many small molecule kinase inhibitors (SMKIs), used predominantly in cancer therapy, have been implicated in serious clinical cardiac adverse events, which…”
Get full text

SENTI-101, a Preparation of Mesenchymal Stromal Cells Engineered to Express IL12 and IL21, Induces Localized and Durable Antitumor Immunity in Preclinical Models of Peritoneal Solid Tumors by Gonzalez-Junca, Alba, Liu, Frances D, Nagaraja, Archana S, Mullenix, Alyssa, Lee, Chen-Ting, Gordley, Russell M, Frimannsson, Daniel O, Maller, Ori, Garrison, Brian S, Iyer, Dharini, Benabbas, Anissa, Truong, Tiffany A, Quach, Allison, Tian, Mengxi, Martinez, Rowena, Savur, Rishi, Perry-McNamara, Alyssa, Nguyen, Denny, Almudhfar, Niran, Blanco, Carmina, Huynh, Christina, Nand, Asish, Lay, Yu-An E, Magal, Ashita, Mangalampalli, Sravani, Lee, Philip J, Lu, Timothy K, Lee, Gary

“…Advanced peritoneal carcinomatosis including high-grade ovarian cancer has poor prognoses and a poor response rate to current checkpoint inhibitor…”
Get full text

Abstract 4246: SENTI-101, a novel genetically modified allogeneic cell product expressing IL12 and IL21, elicits a tumor-localized, robust, and multimodal immune response in preclinical models of solid tumors by Gonzalez, Alba, Liu, Frances D., Nagaraja, Archana, Mullenix, Alyssa, Gordley, Russell M., Frimannsson, Daniel O., Benabbas, Anissa, Lee, Chen-Ting, Truong, Tiffany A., Quach, Allison, Tian, Mengxi, Martinez, Rowena, Savur, Rishi, Perry-McNamara, Alyssa, Wang, Don-Hong, Maller, Ori, Iyer, Dharini, Magal, Ashita, Mangalampalli, Sravani, Huynh, Christina J., Blanco, Carmina C., Lin, Jack T., Garrison, Brian S., Lee, Philip, Lu, Timothy K., Lee, Gary

“…Abstract While immunotherapies based on single recombinant cytokines such as IL12 and IL21 have shown great promise in preclinical models of solid tumors,…”
Get full text

Abstract 3195: Preclinical development of SENTI-202, an off-the-shelf logic gated CAR-NK cell therapy, for the treatment of CD33/FLT3+ hematologic malignancies including AML by Gonzalez, Alba, Hong, Enping, Yucel, Gozde, Leitner, Elizabeth, Chinta, Pearley, Deng, Han, Li, Ian, Lam, Alice, Bakir, Abla, Lee, Brandon, Chakraborty, Papia, Blanco, Carmina, Lee, Chen-Ting, Almudhfar, Niran, Tian, Mengxi, Song, Wenqi, Banicki, Andrew, Contreras, Otto, Gieldin, Martin, Garrison, Brian, Lu, Timothy K., Rajangam, Kanya

“…Abstract CD33 and FLT3 are validated targets for myeloid malignancies, including acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). These…”
Get full text